XML 65 R49.htm IDEA: XBRL DOCUMENT v3.6.0.2
Collaborative Research, Development and License Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2016
Nov. 30, 2014
Dec. 31, 2008
Dec. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2012
Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]                  
Unused development funding advanced by AstraZeneca           $ 7,345,000      
Accrued current liabilities       $ 11,192,000 $ 11,192,000 15,337,000      
Maximum                  
Deferred Revenue Arrangement [Line Items]                  
Additional revenue recognized         100,000,000        
Astra Zeneca                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration Revenue             $ 5,400,000   $ 3,000,000
Payments received for development work             8,000,000 $ 6,000,000 $ 3,000,000
Additional collaboration revenue         800,000        
Milestone payments earned $ 7,200,000       7,200,000        
Unused development funding advanced by AstraZeneca           7,400,000      
Milestone revenue recognition       7,200,000 103,000 1,635,000 $ 2,174,000    
Accrued current liabilities       200,000 200,000        
Deferred revenue       0 0 2,700,000      
Glaxo Smith Kline                  
Deferred Revenue Arrangement [Line Items]                  
Collaboration Revenue   $ 2,500,000 $ 10,000,000            
Deferred revenue       $ 0 $ 0 $ 0